Replies to post #226242 on Biotech Values

[DewDiligence]

By my arithmetic, ENTA would be EPS-accretive immediately to certain prospective suitors at a price as high as $110/sh, making reasonable assumptions about cost synergies and tax rates. (One of the “cost synergies” might be axing the NASH program.)